Feed: "Endpoints News"
By: ENDPOINTS on Wednesday, May 21, 2025
By: ENDPOINTS on Wednesday, May 21, 2025
Moderna pulls application for Covid-flu shot; Another IPO in Hong Kong
Plus, news about Genfit, Ipsen, Accropeutics, Merck KGaA, Alumis and Acelyrin.
endpts.com
May 22, 2025 at 5:02 AM
Feed: "Endpoints News"
By: ENDPOINTS on Wednesday, May 21, 2025
By: ENDPOINTS on Wednesday, May 21, 2025
Feed: "Clinical Trials Arena"
By: Abigail Beaney on Wednesday, May 21, 2025
By: Abigail Beaney on Wednesday, May 21, 2025
Accropeutics’ TYK2/JAK1 inhibitor meets endpoints in Phase II psoriasis trial
Accropeutics said the Phase II trial of AC-201 will support the drugs progression to a Phase III trial in plaque psoriasis.
www.clinicaltrialsarena.com
May 22, 2025 at 2:02 AM
Feed: "Clinical Trials Arena"
By: Abigail Beaney on Wednesday, May 21, 2025
By: Abigail Beaney on Wednesday, May 21, 2025
Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment#China#Suzhou#Accropeutics#Plaque_Psoriasis#AC-201
Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment
Accropeutics has announced promising Phase 2 trial results for AC-201, an oral TYK2/JAK1 inhibitor, aimed at treating plaque psoriasis, paving the way for further development.
third-news.com
May 21, 2025 at 12:57 AM
Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment#China#Suzhou#Accropeutics#Plaque_Psoriasis#AC-201
Accropeutics Secures $12 Million in Series B Plus Financing to Advance Revolutionary Biotech Treatments#United_States#New_York#biotech#Series_B#Accropeutics
Accropeutics Secures $12 Million in Series B Plus Financing to Advance Revolutionary Biotech Treatments
Accropeutics Inc. has successfully closed a $12 million Series B Plus financing round to enhance their clinical trials, focusing on immune-mediated diseases.
third-news.com
March 14, 2025 at 8:37 AM
Accropeutics Secures $12 Million in Series B Plus Financing to Advance Revolutionary Biotech Treatments#United_States#New_York#biotech#Series_B#Accropeutics
Accropeutics Advances with First Patient Dosed in Phase Ib Trial for Innovative Ulcerative Colitis Treatment#USA#New_York#Ulcerative_Colitis#Accropeutics#AC-101
Accropeutics Advances with First Patient Dosed in Phase Ib Trial for Innovative Ulcerative Colitis Treatment
Accropeutics Inc. has announced the dosing of the first patient in its Phase Ib clinical trial for AC-101, aimed at treating moderate to severe Ulcerative Colitis.
third-news.com
February 13, 2025 at 10:57 AM
Accropeutics Advances with First Patient Dosed in Phase Ib Trial for Innovative Ulcerative Colitis Treatment#USA#New_York#Ulcerative_Colitis#Accropeutics#AC-101
Accropeutics Secured $12 Million in Series B Plus Financing
www.viv-media.com
March 14, 2025 at 1:50 PM
Thoughts on this? >> Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints
in Chinese biotech's first phase 2 win >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #biotech #pharmaceutical
in Chinese biotech's first phase 2 win >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #biotech #pharmaceutical
Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints
in Chinese biotech's first phase 2 win
Accropeutics’ drug has hit the goals of a phase 2 psoriasis trial in China, prompting the biotech to pledge to “accelerate” the TYK2/JAK1 inhibitor’s clinical development.
dlvr.it
May 21, 2025 at 2:30 PM
Thoughts on this? >> Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints
in Chinese biotech's first phase 2 win >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #biotech #pharmaceutical
in Chinese biotech's first phase 2 win >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #biotech #pharmaceutical
Thoughts on this? >> Accropeutics Announces Positive Data from Phase 2 Trial of
AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment
of Moderate-to-Severe Plaque Psoriasis >> Comment below! #healthtech #industry40 #AI #mhealth #IoT
AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment
of Moderate-to-Severe Plaque Psoriasis >> Comment below! #healthtech #industry40 #AI #mhealth #IoT
Accropeutics Announces Positive Data from Phase 2 Trial of
AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment
of Moderate-to-Severe Plaque Psoriasis
Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation Efficacy and safety findings from this Phase 2 trial support advancing AC-201 into Phase 3 development for …
dlvr.it
May 21, 2025 at 1:59 AM
Thoughts on this? >> Accropeutics Announces Positive Data from Phase 2 Trial of
AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment
of Moderate-to-Severe Plaque Psoriasis >> Comment below! #healthtech #industry40 #AI #mhealth #IoT
AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment
of Moderate-to-Severe Plaque Psoriasis >> Comment below! #healthtech #industry40 #AI #mhealth #IoT
Thoughts on this? >> Altimmune to put its incretin into addiction trials; Tarsus
aims to raise $125M: Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics,… >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing
aims to raise $125M: Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics,… >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing
Altimmune to put its incretin into addiction trials; Tarsus
aims to raise $125M
Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics, Cadrenal and Inovio: Altimmune to test its incretin in addiction: Following the path set by Novo Nordisk last week, Altimmune said Thursday at its R ...
dlvr.it
March 14, 2025 at 4:39 PM
Thoughts on this? >> Altimmune to put its incretin into addiction trials; Tarsus
aims to raise $125M: Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics,… >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing
aims to raise $125M: Plus, news about Heidelberg, Accropeutics, Allarity Therapeutics,… >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing
Thoughts on this? >> Accropeutics Secured $12 Million in Series B Plus
Financing: Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new… >> Comment below! #AI #healthtech #IoT #industry40 #mhealth
Financing: Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new… >> Comment below! #AI #healthtech #IoT #industry40 #mhealth
Accropeutics Secured $12 Million in Series B Plus
Financing
Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). Cash runway…
dlvr.it
March 14, 2025 at 9:15 AM
Thoughts on this? >> Accropeutics Secured $12 Million in Series B Plus
Financing: Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new… >> Comment below! #AI #healthtech #IoT #industry40 #mhealth
Financing: Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new… >> Comment below! #AI #healthtech #IoT #industry40 #mhealth
Accropeutics' oral TYK2/JAK1 inhibitor hits main goals of mid-stage psoriasis study firstwordpharma.com/story/5964794
May 21, 2025 at 10:58 AM
Accropeutics' oral TYK2/JAK1 inhibitor hits main goals of mid-stage psoriasis study firstwordpharma.com/story/5964794